Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Published 2018 View Full Article

Authors

Keywords

Journal

CANCER RESEARCH

Volume 78, Issue 4 Supplement, Pages OT1-01-04-OT1-01-04

Publisher

American Association for Cancer Research (AACR)

Online

2018-02-16

DOI

10.1158/1538-7445.sabcs17-ot1-01-04

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

CANCER RESEARCH

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Create your own webinar